Destiny Pharma updates on partnership discussions in the wake of half-year results

Destiny Pharma PLC’s (AIM:DEST) chief executive Neil Clark joined Proactive after the release of interim results that showed it had made impressive clinical progress with its next-generation antibiotics.

The group is now looking for licensing partners for its phase III-ready asset NTCD-M3. Clark talked to Chris Rhodes about NTCD-M3 and the company’s XF-73 nasal gel.

#destinypharma #aim #lse #healthcare #antibiotics

You might like

© 2022 The Latest StockMarket News and Interviews